Beka Solomon

Summary

Affiliation: Tel Aviv University
Country: Israel

Publications

  1. pmc Filamentous phage as vector-mediated antibody delivery to the brain
    Dan Frenkel
    Department of Molecular Microbiology and Biotechnology, The George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Proc Natl Acad Sci U S A 99:5675-9. 2002
  2. ncbi request reprint Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels
    Idan Rakover
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel
    Neurodegener Dis 4:392-402. 2007
  3. ncbi request reprint Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside
    Michal Arbel
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Trends Immunol 28:511-3. 2007
  4. ncbi request reprint Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    J Alzheimers Dis 9:433-8. 2006
  5. pmc Beneficial effect of antibodies against β- secretase cleavage site of APP on Alzheimer's-like pathology in triple-transgenic mice
    Inna Rabinovich-Nikitin
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 7:e46650. 2012
  6. ncbi request reprint Intravenous immunoglobulin and Alzheimer's disease immunotherapy
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv 69978, Tel Aviv, Israel
    Curr Opin Mol Ther 9:79-85. 2007
  7. ncbi request reprint Immunotherapy for Alzheimer's disease
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel
    Neuropharmacology 59:303-9. 2010
  8. ncbi request reprint Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Rejuvenation Res 11:349-57. 2008
  9. ncbi request reprint Active immunization against Alzheimer's beta-amyloid peptide using phage display technology
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Vaccine 25:3053-6. 2007
  10. doi request reprint Immunotherapeutic strategies for Alzheimer's disease treatment
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    ScientificWorldJournal 9:909-19. 2009

Collaborators

Detail Information

Publications39

  1. pmc Filamentous phage as vector-mediated antibody delivery to the brain
    Dan Frenkel
    Department of Molecular Microbiology and Biotechnology, The George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Proc Natl Acad Sci U S A 99:5675-9. 2002
    ..The ability to image A beta deposits in vivo would arguably provide the most useful diagnostic and monitoring test for early diagnosis of Alzheimer's disease...
  2. ncbi request reprint Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels
    Idan Rakover
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel
    Neurodegener Dis 4:392-402. 2007
    ....
  3. ncbi request reprint Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside
    Michal Arbel
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Trends Immunol 28:511-3. 2007
    ..This work suggests novel avenues for the immunotherapy of Alzheimer's disease...
  4. ncbi request reprint Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    J Alzheimers Dis 9:433-8. 2006
    ....
  5. pmc Beneficial effect of antibodies against β- secretase cleavage site of APP on Alzheimer's-like pathology in triple-transgenic mice
    Inna Rabinovich-Nikitin
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 7:e46650. 2012
    ....
  6. ncbi request reprint Intravenous immunoglobulin and Alzheimer's disease immunotherapy
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv 69978, Tel Aviv, Israel
    Curr Opin Mol Ther 9:79-85. 2007
    ....
  7. ncbi request reprint Immunotherapy for Alzheimer's disease
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel
    Neuropharmacology 59:303-9. 2010
    ..The renewed human phase clinical trials toward improved immunotherapeutic strategies which maintain the beneficial effects without adverse side effects are under further evaluation...
  8. ncbi request reprint Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Rejuvenation Res 11:349-57. 2008
    ..Antibodies generated with the first-generation vaccine might not have the desired therapeutic properties to target the "correct" mechanism, however, new immunological approaches are now under consideration...
  9. ncbi request reprint Active immunization against Alzheimer's beta-amyloid peptide using phage display technology
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Vaccine 25:3053-6. 2007
    ..This immunization procedure led to improvement in cognitive functions and alleviated amyloid pathology in a transgenic mouse (Tg) model of AD...
  10. doi request reprint Immunotherapeutic strategies for Alzheimer's disease treatment
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    ScientificWorldJournal 9:909-19. 2009
    ..Immunotherapy represents fascinating ways to test the amyloid hypothesis and offers genuine opportunities for AD treatment, but requires careful antigen and antibody selection to maximize efficacy and minimize adverse events...
  11. ncbi request reprint Clinical immunologic approaches for the treatment of Alzheimer's disease
    Beka Solomon
    George S Wise Faculty of Life Sciences, Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel
    Expert Opin Investig Drugs 16:819-28. 2007
    ....
  12. ncbi request reprint Antibody-mediated immunotherapy for Alzheimer's disease
    Beka Solomon
    Tel Aviv University, George S Wise Faculty of Life Sciences, Department of Molecular Microbiology and Biotechnology, Ramat Aviv, Tel Aviv 69978, Israel
    Curr Opin Investig Drugs 8:519-24. 2007
    ..Clearly, future therapeutic approaches for Alzheimer's disease depend on increased research into the various mechanisms of immunotherapy to successfully clear Abeta peptides...
  13. ncbi request reprint Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Drugs Today (Barc) 43:333-42. 2007
    ..The data presented support the hypothesis that beta-amyloid peptide plays a central role in Alzheimer's disease, and antibodies which modulate beta-amyloid conformation may lead to immunotherapy of the disease...
  14. ncbi request reprint Filamentous bacteriophage as a novel therapeutic tool for Alzheimer's disease treatment
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    J Alzheimers Dis 15:193-8. 2008
    ..The feasibility of these novel strategies for production and targeting of anti-aggregating antibodies against Abeta plaques to disease affected regions in the CNS may have clinical potential for treatment of Alzheimer's disease...
  15. ncbi request reprint Alzheimer's disease and immunotherapy
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, P O Box 69978, Israel
    Curr Alzheimer Res 1:149-63. 2004
    ..Immunotherapy represents fascinating ways to test the amyloid hypothesis and offers genuine opportunities for AD treatment, but requires careful antigen and antibody selection to maximize efficacy and minimize adverse events...
  16. ncbi request reprint Immunological approach for the treatment of Alzheimer's disease
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    J Mol Neurosci 20:283-6. 2003
    ..These data support the hypotheses that AbetaP plays a central role in AD, and site-directed antibodies that modulate AbetaP conformation might lead toward immunotherapy of the disease...
  17. ncbi request reprint Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Vaccine 23:2327-30. 2005
    ..Performance of such antigens opens up possibilities for development of an efficient, long-lasting immunization procedure for treatment of Alzheimer's disease...
  18. ncbi request reprint Anti-aggregating antibodies, a new approach towards treatment of conformational diseases
    Beka Solomon
    Department of Molecular Microbiology Biotechnology, The George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, 69978, Israel
    Curr Med Chem 9:1737-49. 2002
    ....
  19. ncbi request reprint Towards Alzheimer's disease vaccination
    Beka Solomon
    Department of Molecular Microbiology Biotechnology, Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, 69978, Israel
    Mini Rev Med Chem 2:85-92. 2002
    ....
  20. ncbi request reprint Immunological approaches as therapy for Alzheimer's disease
    Beka Solomon
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Expert Opin Biol Ther 2:907-17. 2002
    ..These data support the hypothesis that AbetaP plays a central role in AD and antibodies which modulate Abeta conformation may lead to immunotherapy of the disease...
  21. ncbi request reprint EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials
    Vered Lavie
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel 69978
    J Mol Neurosci 24:105-13. 2004
    ....
  22. ncbi request reprint Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization
    Dan Frenkel
    Department of Molecular Microbiology and Biotechnology, The George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Vaccine 21:1060-5. 2003
    ..The immunization provoked a considerable reduction in the number of Abeta amyloid plaques in the brain of the transgenic mice and may serve as the basis for anti-Abeta vaccine...
  23. pmc Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease
    Maria Becker
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Proc Natl Acad Sci U S A 104:1691-6. 2007
    ....
  24. ncbi request reprint Antigen-specific therapy of EAE via intranasal delivery of filamentous phage displaying a myelin immunodominant epitope
    Idan S Rakover
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel
    J Neuroimmunol 225:68-76. 2010
    ....
  25. pmc Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies
    Michal Arbel
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Proc Natl Acad Sci U S A 102:7718-23. 2005
    ..Indeed, blocking of the beta-secretase site by these antibodies interfered with BACE activity and inhibited both intracellular and extracellular AbetaP formation in these cells...
  26. ncbi request reprint Generation of anti-beta-amyloid antibodies via phage display technology
    Dan Frenkel
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Vaccine 22:2505-8. 2004
    ..EFRH-phage immunization of a transgenic mouse model of Alzheimer's disease evokes antibodies able to dissolve already formed beta-amyloid plaques, suggesting that they could become a therapeutic approach in treatment of the disease...
  27. ncbi request reprint Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide
    Gili Istrin
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    J Neurosci Res 84:434-43. 2006
    ..Thus, several mechanisms can be considered when examining the effects of IVIg. Our work supports the hypothesis that IVIg interferes by more than one mechanism in clearing AbetaP from the brains of Alzheimer's patients...
  28. ncbi request reprint Deglycosylation of anti-beta amyloid antibodies inhibits microglia activation in BV-2 cellular model
    Sabina Rebe
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel
    Am J Alzheimers Dis Other Demen 20:303-13. 2005
    ..These data suggest that deglycosylation of anti-Abeta antibodies before in vivo administration might prevent microglial overactivation, thus reducing the risk of neuroinflammatory response during passive immunization...
  29. doi request reprint Filamentous phages reduce alpha-synuclein oligomerization in the membrane fraction of SH-SY5Y cells
    Hemi Dimant
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Neurodegener Dis 7:203-5. 2010
    ..Much effort is dedicated to prevent and dissolve AS aggregates, specifically AS oligomers and protofibrils, which are thought to be the more toxic form of aggregates...
  30. ncbi request reprint A novel immunotherapy for Alzheimer's disease: antibodies against the beta-secretase cleavage site of APP
    Michal Arbel
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel
    Curr Alzheimer Res 4:437-45. 2007
    ..The relevance of intra-neuronal accumulation of mainly Abeta42 as an early event in AD pathogenesis suggests that this approach may be applicable as a novel therapeutic strategy in AD treatment...
  31. ncbi request reprint Generation of antibodies against prion protein in wild-type mice via helix 1 peptide immunization
    Michal Arbel
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    J Neuroimmunol 144:38-45. 2003
    ..The generated antibodies recognize the whole prion protein with a high binding constant and the established protocol may lead to an active immunization towards therapeutics of prion disease...
  32. ncbi request reprint Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein
    Sara Orgad
    Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Israel
    FEBS Lett 579:5609-15. 2005
    ..These findings suggest that the scFv restores wild-type properties to mutant p53...
  33. doi request reprint TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants
    Sara Orgad
    Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel
    J Immunother 33:146-54. 2010
    ..Thus, it may be considered as a potential candidate for anticancer treatment, targeting tumors with mutant p53...
  34. ncbi request reprint Inhibition of amyloid precursor protein beta-secretase cleavage site affects survival and motor functions of amyotrophic lateral sclerosis transgenic mice
    Polina Rabinovich-Toidman
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Neurodegener Dis 10:30-3. 2012
    ..The APP cleavage products--soluble APP-β (sAPPβ), amyloidogenic Aβ, and amino-terminal fragment N-APP--mediate a reduction in synaptic transmission, synaptic loss, neurite retraction and, ultimately, programmed cell death...
  35. doi request reprint Modulation effect of filamentous phage on alpha-synuclein aggregation
    Hemi Dimant
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel
    Biochem Biophys Res Commun 383:491-6. 2009
    ..Data presented here show reduced levels of AS soluble aggregates in phage treated cells compared to non-treated cells, suggesting new therapeutics for PD...
  36. ncbi request reprint Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice
    Michal Arbel-Ornath
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    J Alzheimers Dis 22:469-82. 2010
    ....
  37. doi request reprint Inhibition of amyloid precursor protein processing leads to downregulation of apoptotic genes in Alzheimer's disease animal models
    Inna Rabinovich-Nikitin
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    Neurodegener Dis 13:107-9. 2014
    ....
  38. ncbi request reprint Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide
    Weihong Pan
    Veterans Affairs Medical Center and Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA
    Exp Biol Med (Maywood) 227:609-15. 2002
    ..The presence of mAbmc1 also caused significant reduction of the influx of Abeta into the brain after perfusion. Therefore, effective antibodies to Abeta can reduce the influx of Abeta(1-40) into the brain...
  39. ncbi request reprint A neuroimmunologist's perspective on Alzheimer's disease therapy
    Beka Solomon
    Expert Rev Neurother 7:439-41. 2007